BioSignal Scientific Trust StandardContinuously reviewed using the BioSignal Scientific Evaluation Framework
View MethodologyVitamin D
Cholecalciferol (Vitamin D₃)
Vitamin D is a hormone precursor essential for correcting deficiency and supporting bone mineralization, but large trials show it does not broadly prevent disease in people who already have enough.
If you're here because…
Jump to the part of this record most relevant to your question. These are guides to information, not recommendations.
How confident is BioSignal?
One overall judgement, then the independent dimensions behind it — each on the same scale.
For preventing and treating deficiency and supporting bone health in at-risk groups, vitamin D is effective with high confidence. For broad disease prevention in already-replete adults, the largest trials are null, and confidence in that null is also high. A few extra-skeletal uses remain promising but unproven.
Biological Role
High confidenceVitamin D's role as a hormone precursor governing calcium/phosphate handling and bone mineralization is well established physiology.
Human Evidence
High confidenceLarge, well-conducted randomized trials and an authoritative guideline provide strong human evidence, both for benefit in deficiency and for the absence of benefit in replete adults.
Supplement Benefit
Moderate confidenceBenefit is clear for correcting deficiency and supporting bone, but supplementing already-replete people does not reduce fractures, cancer, cardiovascular events, or mortality.
Safety Confidence
High confidenceAt recommended intakes vitamin D is well tolerated; risk arises from chronic excess (hypercalcemia) and from high intermittent bolus dosing.
Research Activity
HighVitamin D remains an active research area spanning deficiency-targeted trials, autoimmune signals, diabetes subgroups, and dosing safety.
BioSignal Bottom Line
The honest shape of the evidence in five parts — what we know, what we think, what we don't, what's being studied, and what could change our view.
What We Know
Vitamin D is required for calcium handling and bone mineralization, and correcting deficiency prevents and treats rickets in children and osteomalacia in adults.
What We Think
Benefit concentrates where a deficiency exists to correct. In already-replete adults, routine supplementation does not prevent fractures, cancer, cardiovascular disease, or death.
What We Don't Know
The right blood level to target for non-bone outcomes, whether benefits hide in the deficient subgroups of the big trials, and whether the autoimmune and cancer-mortality signals are real.
Active Research
Research is testing vitamin D in deficient populations, replicating an autoimmune-disease signal, probing high-risk prediabetes, and clarifying daily-versus-bolus dosing safety.
What Could Change Our Mind
Large trials enrolling genuinely deficient populations, or confirmation of the autoimmune and cancer-mortality signals, could expand confidence in benefits beyond deficiency correction.
Does it work?
The most common public claims about NAD+, each weighed against the current evidence — what's supported, what's mixed, and what isn't established.
“Vitamin D is required for bone health and corrects rickets and osteomalacia”
Established physiology and global consensus: adequate vitamin D is necessary for normal mineralization, and correcting deficiency prevents and treats nutritional rickets and osteomalacia. This is vitamin D's core, non-negotiable role.
SupportedHigh confidence“Everyone should take vitamin D and get their level tested”
The current guideline recommends against routine testing in generally healthy people and does not endorse universal higher-dose supplementation, instead targeting specific groups. Universal testing and supplementation are not supported.
Not EstablishedModerate confidence“Vitamin D supplementation prevents fractures in the general population”
In a large trial of midlife and older adults not selected for deficiency, vitamin D did not reduce fractures versus placebo. The result speaks to replete adults, not to deficient or osteoporotic individuals.
Not EstablishedModerate confidence“Vitamin D prevents cancer”
In the VITAL trial, vitamin D did not reduce cancer incidence. An exploratory hypothesis about reduced cancer mortality or advanced disease remains unproven and is not a reason to supplement.
Not EstablishedModerate confidence“Vitamin D prevents cardiovascular disease”
The VITAL trial found no reduction in major cardiovascular events with vitamin D versus placebo in a largely replete population. Vitamin D is not a cardiovascular-prevention therapy.
Not EstablishedModerate confidence“Vitamin D reduces all-cause mortality”
The D-Health trial in older adults found no reduction in all-cause mortality, and guidance concurs that routine supplementation does not lower mortality in general populations. Vitamin D is not a longevity intervention for replete adults.
Not EstablishedModerate confidence“Vitamin D prevents type 2 diabetes”
The D2d trial in prediabetes was null overall, but subgroup and deficiency-focused analyses suggested possible benefit, on which the guideline suggests vitamin D specifically for high-risk prediabetes. Not a general diabetes-prevention tool.
Mixed EvidenceLimited evidence“Vitamin D reduces the risk of autoimmune disease”
A VITAL analysis associated vitamin D with a modest reduction in incident autoimmune disease — one of the more credible extra-skeletal signals, but a single major trial that warrants replication. Promising, not established.
Insufficient EvidenceLimited evidence“Vitamin D prevents respiratory infections and boosts immunity”
A large meta-analysis found at most a small protective effect against acute respiratory infections, with substantial heterogeneity and results sensitive to dose and baseline status. Not a reliable way to boost immunity in replete people.
Mixed EvidenceLimited evidence“Vitamin D prevents falls in older adults”
Guideline synthesis does not support routine higher-dose vitamin D for fall prevention, and flags that high intermittent bolus dosing has been associated with more falls. Ensure adequacy with modest daily dosing rather than megadose boluses.
Mixed EvidenceModerate confidence
Practical takeaways
The current evidence, distilled to five points.
- Vitamin D is essential for correcting deficiency and supporting bone; ensure adequacy in at-risk groups.
- It is not a general-population preventive for fractures, cancer, cardiovascular disease, or mortality in replete adults.
- Benefit concentrates where a deficiency exists to correct — the single most useful lens for reading the evidence.
- A few extra-skeletal uses (autoimmune, high-risk prediabetes, infection) are promising but unproven.
- More is not better: chronic very high doses risk hypercalcemia, and high bolus dosing may increase falls.
Dosages used in human studies
The doses researchers have actually studied — summarised for understanding, not as guidance.
| Population | Intervention | Dose | Duration | Primary Outcome | Study Notes |
|---|---|---|---|---|---|
| Most healthy adults | Oral vitamin D (reference intake) | ~600 IU/day | Ongoing | Meeting recommended dietary intake | Reference intake for most ages; educational, not a prescription |
| Older adults | Oral vitamin D (reference intake) | ~800 IU/day | Ongoing | Adequacy and bone health | Higher reference intake for older ages |
| Midlife and older adults (VITAL) | Oral vitamin D₃, daily | 2000 IU/day | Multiple years | Cancer, cardiovascular events, fractures | Largely replete population; hard endpoints were null |
| Adults with prediabetes (D2d) | Oral vitamin D₃, daily | 4000 IU/day | Multiple years | Progression to type 2 diabetes | Overall null; subgroup signals hypothesis-generating |
| Older adults (D-Health) | Oral vitamin D₃, monthly bolus | 60,000 IU/month | Multiple years | All-cause mortality | Bolus regimen; no mortality reduction observed |
BioSignal Note. These protocols summarise doses used in published human research. They are provided for educational purposes and should not be interpreted as treatment recommendations.
What kinds of evidence exist?
A high-level view of the current evidence landscape by category. Counts are intentionally unquantified until sourcing is complete.
- Prototype
Human Studies
Very large randomized trials with pre-specified hard endpoints, concentrated in fracture, cancer, cardiovascular, mortality, and diabetes outcomes.
- Prototype
Mechanistic Evidence
The hormone-precursor pathway and its role in calcium/phosphate handling and bone mineralization are established physiology.
- Prototype
Clinical Guidance
A current endocrine-society clinical practice guideline and a global consensus on nutritional rickets anchor the evidence base.
- Prototype
Systematic Reviews
Meta-analyses synthesise the extra-skeletal literature, including respiratory infection, where the signal is small and heterogeneous.
- Prototype
Research Activity
Ongoing work in deficiency-targeted trials, autoimmune replication, high-risk prediabetes, and dosing safety.
How did we get here?
The chronological arc of how scientific understanding evolved, from foundational biology to current clinical research.
Deficiency Physiology
Vitamin D was established as essential for calcium handling and bone mineralization, with deficiency causing rickets and osteomalacia.
Global Deficiency Consensus
Consensus recommendations formalised prevention and management of nutritional rickets, cementing the deficiency-correction role.
Large Prevention Trials
Very large randomized trials tested broad disease prevention in replete adults and consistently found null results for fractures, cancer, cardiovascular events, and mortality.
Current Guidance & Open Questions
A current guideline targets specific groups and advises against routine testing, while research continues on autoimmune, diabetes, and infection signals and on dosing safety.
Understand the science in detail
Deeper explanations and FAQs — definitions, mechanisms, and how the science is studied. Open any question to go further.
Vitamin D is not strictly a vitamin — it is the precursor to a hormone. It is made in skin on sunlight exposure or obtained from diet and supplements, then converted in the body to an active form that regulates calcium and phosphate. The form measured in blood to define status is 25-hydroxyvitamin D.
The active hormone acts through a receptor expressed in many tissues. Its best-defined role is promoting intestinal calcium and phosphate absorption to support bone mineralization. Because the receptor is widely expressed, immune and metabolic roles are biologically plausible — but plausibility is not proof, and randomized trials settle whether supplementing replete people helps.
Evidence spans established deficiency physiology, a global rickets consensus, and an authoritative endocrine-society guideline, alongside very large randomized trials (such as VITAL, D-Health, and D2d) testing hard outcomes like fractures, cancer, cardiovascular events, mortality, and diabetes. A recurring theme is that most large trials enrolled already-replete people.
The current guideline recommends against routine testing in generally healthy people and does not endorse universal higher-dose supplementation. It suggests empiric vitamin D for specific groups instead. Targeting the people who actually benefit is more defensible than treating the whole population.
Yes. At recommended intakes vitamin D is well tolerated, but sustained very high doses can cause hypercalcemia, with harms that can include kidney stones and, in severe cases, renal and cardiovascular effects. High intermittent bolus dosing has also been linked to more falls. More is not better. This is educational information, not medical advice.
Is it safe?
What is reasonably known, kept clearly separate from what remains uncertain or warrants caution.
What's reasonably known
Known Safety Profile
At recommended intakes vitamin D is well tolerated. The main risks arise from excess and from dosing regimen, not from adequacy.
Commonly Reported Issues
- Generally well tolerated at recommended intakes
- Symptoms of excess (e.g. nausea) reflect hypercalcemia from sustained very high doses
What's uncertain or warrants caution
Long-Term Unknowns
The best status threshold for non-skeletal outcomes, and whether benefits exist specifically in deficient subgroups, remain unresolved; effects in some under-studied groups are less fully characterised.
Populations Requiring Caution
- People with hypercalcemia (clinician oversight required)
- People with granulomatous diseases such as sarcoidosis, or some lymphomas
- People with primary hyperparathyroidism or chronic kidney disease
- Anyone considering high doses or megadosing (avoid without clinician guidance)
Evidence Limitations
Most large trials enrolled already-replete populations, limiting power to detect deficiency-specific benefit; bolus versus daily dosing complicates comparison; long-latency outcomes such as cancer may exceed trial length. High intermittent bolus dosing has been associated with increased falls in some trials.
Educational information only. Not medical advice.
What do scientists agree on?
Where the science is settled, where it is genuinely contested, and where it is still open.
Broad Agreement
Strongly supported by consistent evidence.
- Adequate vitamin D is required for calcium/phosphate handling and normal bone mineralization.
- Correcting deficiency prevents and treats rickets and osteomalacia.
- In already-replete adults, routine supplementation does not reduce fractures, cancer, cardiovascular events, or all-cause mortality.
- At recommended intakes vitamin D is well tolerated; excess and high-bolus dosing carry the main risks.
Active Debate
Evidence is mixed or experts disagree.
- The optimal blood level to target for non-skeletal outcomes.
- The value of population-wide screening and supplementation.
- How strongly to weight subgroup and post-hoc signals (cancer mortality, diabetes subgroups).
Unknowns
Important questions that remain unanswered.
- Whether the large null trials conceal real benefits in their deficient subgroups.
- Whether the autoimmune-disease and cancer-mortality signals are real.
- The best dose, form, and frequency, and effects in under-studied groups.
What remains unknown?
The questions the current evidence cannot yet answer — and what it would take to answer them.
- What is the right blood level to target for outcomes beyond bone?
- Do the big null trials hide real benefits in their deficient subgroups?
- Is the modest autoimmune-disease signal real and replicable?
- Does daily (rather than bolus) dosing in deficient populations change outcomes?
Large trials enrolling genuinely deficient populations, or confirmation of the autoimmune and cancer-mortality signals, could expand confidence in benefits beyond deficiency correction.
Connected Science
How this record connects to the wider science. Each node will open its own Signal Record as the graph grows.
The beginning of the BioSignal Knowledge Graph — interactive graph view coming in a future sprint.
Evidence & References
Every reference below was verified to its source during scientific review. Links open the original study.
Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL)
Supplemental vitamin D and incident fractures in midlife and older adults (VITAL)
Vitamin D and marine omega-3 fatty acid supplementation and incident autoimmune disease (VITAL)
The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality
Vitamin D supplementation and prevention of type 2 diabetes (D2d)
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials
Global consensus recommendations on prevention and management of nutritional rickets
Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline
Version History
Every Signal Record evolves as the science evolves. Changes are tracked here.
First published Signal Record for the Alpha launch, distilled from Gold Standard Record #002. Verified references attached. Future versions will track scientific updates, evidence changes, and review history.